Redirecting to https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma#:~:text=On%20March%2019%2C%202025%2C%20the,HER2%2Dpositive%20gastric%20or%20gastroesophageal...

Click here if your browser doesn't automatically take you to this page.